Hai Wang Bio-raise 1.4 billion of money to hit the pharmaceutical logistics

Sea King February 18 released "Non-public offering stock plan" said, the company intends to raise funds not more than 1.4435 billion yuan, for the pharmaceutical business Sunshine Centralized distribution center construction projects, Sea King pharmaceutical solid preparation production line renovation project,　　Hai Wang Pharmaceutical anti-tumor freeze-Dry preparation workshop construction projects and Hangzhou Hai Wang health care products production line construction projects, non-public offering price of not less than 10.37 yuan per share, the number of additional issues not exceeding 139.2 million shares. The announcement showed that the pharmaceutical business "Sunshine concentrated Distribution" project became the focus of the Sea King biological fundraising.　　The total investment amount of the project is 1,539,703,600 Yuan, the implementation of the main body for the company's wholly-owned subsidiary Neptune Galaxy, the company intends to invest in fund-raising 110,220.910,000 Yuan, by Sea King Biology to raise funds 11,022.90,000 yuan and Sea King Galaxy to raise funds 99,198 820,000 yuan joint investment. China has been the world's fastest-growing pharmaceutical market in recent years, and is expected to become the world's second-largest pharmaceutical market after the United States by 2020, the Sea King said.　　At the same time, with the mature market by a small number of large pharmaceutical companies monopolized the pattern, the current China's pharmaceutical circulation industry concentration is still low, the enterprise scale is generally small, industry integration is inevitable, business model leading large-scale pharmaceutical business enterprises face the historical opportunity to integrate industry resources.　　At present, Sea King Biology has formed the "sunshine concentrated distribution" of the circulation business model, in accordance with the National Drug Management policy unchanged, the implementation of the provincial centralized network of public bidding and procurement price unchanged and the right to choose the hospital drug use, the company as the main distributor to complete the regional leading hospital drug use centralized distribution work. Sea King Biology in the announcement, the company will be in Weihai, Shandong Heze, Shandong Zaozhuang, Henan Nanyang, Hubei Xiaogan Five set up a subsidiary to build Sunshine Centralized distribution center and is responsible for operation and management. The construction of each distribution center is implemented in two phases, the first phase is completed, the project can be put into operation, the two project is mainly to increase the warehouse capacity and other ancillary facilities to enhance the distribution capacity.